RLAY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.32%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,084,089.25

Relay Therapeutics Insider Trading History Chart

Relay Therapeutics Share Price & Price History

^$7.97

▲ +0.39 (5.15%)

As of 09/19/2024 01:28 PM ET

Days: 30 | 90 | 365

Unveiled: NVIDIA’s "Secret Royalty" Program

From Behind the Markets | Ad

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

Relay Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/31/2024	Peter Rahmer	Insider	Sell	13,708	$8.19	$112,268.52	391,929
7/29/2024	Peter Rahmer	Insider	Sell	13,523	$8.54	$115,486.42	420,765
7/29/2024	Thomas Catinazzo	CFO	Sell	10,780	$8.56	$92,276.80	319,650
7/26/2024	Sanjiv Patel	CEO	Sell	36,706	$9.07	$332,923.42	766,130
6/27/2024	Donald A. Bergstrom	Insider	Sell	648	$6.26	$4,056.48	526,779
6/27/2024	Thomas Catinazzo	CFO	Sell	9,373	$6.24	$58,487.52	330,430
6/5/2024	Peter Rahmer	Insider	Sell	20,450	$7.06	$144,377.00	432,425
6/3/2024	Peter Rahmer	Insider	Sell	19,864	$6.47	$128,520.08	493,470
4/29/2024	Peter Rahmer	Insider	Sell	1,345	$6.38	$8,581.10	513,334
4/29/2024	Thomas Catinazzo	CFO	Sell	1,695	$6.38	$10,814.10	339,803
3/27/2024	Donald A. Bergstrom	Insider	Sell	765	$7.70	$5,890.50	530,113
3/27/2024	Thomas Catinazzo	CFO	Sell	348	$7.70	$2,679.60	341,498
1/29/2024	Peter Rahmer	Insider	Sell	1,651	$9.64	$15,915.64	514,977
1/29/2024	Thomas Catinazzo	CFO	Sell	2,005	$9.64	$19,328.20	341,846
12/27/2023	Peter Rahmer	Insider	Sell	244	$11.51	$2,808.44	316,628
12/27/2023	Thomas Catinazzo	CFO	Sell	294	$11.51	$3,383.94	143,851
10/30/2023	Peter Rahmer	Insider	Sell	1,354	$6.03	$8,164.62	316,872
10/30/2023	Thomas Catinazzo	CFO	Sell	1,697	$6.03	$10,232.91	144,145
9/27/2023	Donald A. Bergstrom	Insider	Sell	648	$8.38	$5,430.24	238,484
9/27/2023	Thomas Catinazzo	CFO	Sell	294	$8.38	$2,463.72	145,842
7/28/2023	Peter Rahmer	Insider	Sell	1,352	$11.80	$15,953.60	316,808
7/28/2023	Thomas Catinazzo	CFO	Sell	1,693	$11.80	$19,977.40	146,136
6/27/2023	Donald A. Bergstrom	Insider	Sell	647	$12.12	$7,841.64	240,587
6/27/2023	Thomas Catinazzo	CFO	Sell	294	$12.12	$3,563.28	147,829
4/28/2023	Peter Rahmer	Insider	Sell	739	$11.16	$8,247.24	157,504
4/28/2023	Thomas Catinazzo	CFO	Sell	863	$11.16	$9,631.08	149,272
3/27/2023	Peter Rahmer	Insider	Sell	297	$15.36	$4,561.92	158,243
3/27/2023	Thomas Catinazzo	CFO	Sell	347	$15.36	$5,329.92	150,135
2/8/2023	Sanjiv Patel	CEO	Sell	14,000	$20.98	$293,720.00
1/30/2023	Peter Rahmer	Insider	Sell	740	$21.56	$15,954.40	158,540
1/30/2023	Thomas Catinazzo	CFO	Sell	864	$21.56	$18,627.84	150,482
1/18/2023	Sanjiv Patel	CEO	Sell	28,000	$20.87	$584,360.00	254,554
1/12/2023	Brian Adams	Insider	Sell	9,994	$20.00	$199,880.00	51,531
12/27/2022	Donald A. Bergstrom	Insider	Sell	980	$14.49	$14,200.20	85,886
12/27/2022	Thomas Catinazzo	CFO	Sell	445	$14.49	$6,448.05	50,231
11/10/2022	Sanjiv Patel	CEO	Sell	28,000	$20.00	$560,000.00	254,554
11/8/2022	Sanjiv Patel	CEO	Sell	14,000	$20.18	$282,520.00	254,554
11/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.75	$182,000.00	86,866
10/28/2022	Andy Porter	Insider	Sell	448	$21.54	$9,649.92	45,164
10/28/2022	Thomas Catinazzo	CFO	Sell	1,099	$21.54	$23,672.46	50,676
10/12/2022	Sanjiv Patel	CEO	Sell	14,000	$21.18	$296,520.00	254,554
10/3/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.43	$179,440.00	88,683
9/27/2022	Brian Adams	Insider	Sell	294	$22.73	$6,682.62	62,548
9/27/2022	Thomas Catinazzo	CFO	Sell	443	$22.73	$10,069.39	51,775
9/14/2022	Sanjiv Patel	CEO	Sell	14,000	$23.47	$328,580.00	254,554
9/8/2022	Mark Murcko	Director	Sell	25,000	$29.95	$748,750.00	996,952
9/8/2022	Thomas Catinazzo	CFO	Sell	26,257	$30.00	$787,710.00	52,218
8/24/2022	Donald A. Bergstrom	Insider	Sell	15,000	$25.00	$375,000.00	89,659
8/5/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	89,659
7/28/2022	Andy Porter	Insider	Sell	452	$21.27	$9,614.04	45,871
7/28/2022	Thomas Catinazzo	CFO	Sell	734	$21.26	$15,604.84	52,218
7/6/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	91,494
6/27/2022	Andy Porter	Insider	Sell	265	$20.31	$5,382.15	46,323
6/27/2022	Thomas Catinazzo	CFO	Sell	300	$20.31	$6,093.00	52,952
6/24/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	92,493
5/2/2022	Donald A. Bergstrom	Insider	Sell	13,000	$24.62	$320,060.00	92,493
4/28/2022	Donald A. Bergstrom	Insider	Sell	1,811	$25.57	$46,307.27	92,493
4/28/2022	Thomas Catinazzo	CFO	Sell	725	$25.57	$18,538.25	53,252
4/13/2022	Sanjiv Patel	CEO	Sell	28,000	$31.95	$894,600.00	253,740
4/1/2022	Donald A. Bergstrom	Insider	Sell	18,000	$30.32	$545,760.00	94,304
3/29/2022	Andy Porter	Insider	Sell	294	$29.87	$8,781.78
3/29/2022	Thomas Catinazzo	CFO	Sell	282	$29.87	$8,423.34
3/24/2022	Donald A. Bergstrom	Insider	Sell	10,000	$30.00	$300,000.00
3/24/2022	Thomas Catinazzo	CFO	Sell	13,286	$30.00	$398,580.00
3/10/2022	Donald A. Bergstrom	Insider	Sell	10,000	$25.00	$250,000.00
3/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$23.88	$191,040.00
2/22/2022	Donald A. Bergstrom	Insider	Sell	22,994	$20.94	$481,494.36
12/27/2021	Andy Porter	Insider	Sell	260	$33.10	$8,606.00
12/27/2021	Thomas Catinazzo	SVP	Sell	295	$33.10	$9,764.50
11/15/2021	Brian Adams	General Counsel	Sell	6,500	$35.42	$230,230.00
11/15/2021	Thomas Catinazzo	SVP	Sell	22,500	$35.40	$796,500.00
10/15/2021	Donald A. Bergstrom	Insider	Sell	30,000	$34.15	$1,024,500.00
9/27/2021	Donald A. Bergstrom	Insider	Sell	646	$36.87	$23,818.02
9/27/2021	Thomas Catinazzo	SVP	Sell	293	$36.87	$10,802.91

Who are Nvidia’s New Silent Partners?

From Weiss Ratings | Ad

Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.

I call these Nvidia’s “Silent Partners.”

SEC Filings (Institutional Ownership Changes) for Relay Therapeutics (NASDAQ:RLAY)

96.98% of Relay Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Relay Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2024	Algert Global LLC	476,888	$3.11M	0.1%	+57.9%	0.356%
8/16/2024	Driehaus Capital Management LLC	616,220	$4.02M	0.0%	+54.9%	0.460%
8/15/2024	Susquehanna Fundamental Investments LLC	53,442	$0.35M	0.0%	+248.7%	0.040%
8/15/2024	The Manufacturers Life Insurance Company	215,588	$1.41M	0.0%	-8.3%	0.161%
8/15/2024	Millennium Management LLC	1,149,177	$7.49M	0.0%	+404.2%	0.858%
8/15/2024	Deerfield Management Company L.P. Series C	46,702	$0.30M	0.0%	N/A	0.035%
8/15/2024	AQR Capital Management LLC	67,243	$0.44M	0.0%	+362.2%	0.050%
8/15/2024	Caxton Associates LP	107,568	$0.70M	0.0%	-17.8%	0.080%
8/14/2024	Squarepoint Ops LLC	144,986	$0.95M	0.0%	N/A	0.108%
8/14/2024	Marshall Wace LLP	276,702	$1.80M	0.0%	N/A	0.207%
8/14/2024	Logos Global Management LP	1,300,000	$8.48M	0.7%	N/A	0.979%
8/14/2024	Integral Health Asset Management LLC	750,000	$4.89M	0.5%	+3.4%	0.560%
8/14/2024	EverSource Wealth Advisors LLC	5,750	$37K	0.0%	N/A	0.004%
8/14/2024	ProShare Advisors LLC	20,883	$0.14M	0.0%	-20.3%	0.016%
8/14/2024	Profund Advisors LLC	36,418	$0.24M	0.0%	-49.7%	0.027%
8/13/2024	Ensign Peak Advisors Inc	55,450	$0.36M	0.0%	+24.3%	0.042%
8/13/2024	Thrivent Financial for Lutherans	120,011	$0.78M	0.0%	N/A	0.090%
8/12/2024	Hsbc Holdings PLC	41,339	$0.26M	0.0%	+118.3%	0.031%
8/12/2024	E Fund Management Co. Ltd.	11,778	$77K	0.0%	-46.3%	0.009%
8/9/2024	Renaissance Technologies LLC	909,037	$5.93M	0.0%	+19.1%	0.685%
8/9/2024	Dimensional Fund Advisors LP	1,520,340	$9.91M	0.0%	-5.0%	1.145%
8/8/2024	Federated Hermes Inc.	312,444	$2.04M	0.0%	-7.1%	0.235%
8/8/2024	DekaBank Deutsche Girozentrale	60,000	$0.39M	0.0%	-13.0%	0.045%
8/8/2024	American Century Companies Inc.	178,088	$1.16M	0.0%	+19.4%	0.134%
8/6/2024	Los Angeles Capital Management LLC	106,169	$0.69M	0.0%	+661.7%	0.080%
8/6/2024	Candriam S.C.A.	703,429	$4.59M	0.0%	+38.4%	0.530%
8/5/2024	Victory Capital Management Inc.	76,539	$0.50M	0.0%	+11.2%	0.058%
8/3/2024	TD Asset Management Inc	206,056	$1.34M	0.0%	-42.5%	0.155%
8/1/2024	Rhumbline Advisers	163,895	$1.07M	0.0%	+4.8%	0.123%
7/29/2024	Principal Financial Group Inc.	14,580	$95K	0.0%	-43.4%	0.011%
7/26/2024	Allspring Global Investments Holdings LLC	38,656	$0.25M	0.0%	+304.0%	0.029%
7/26/2024	Bank of New York Mellon Corp	354,667	$2.31M	0.0%	+15.7%	0.267%
7/25/2024	Baillie Gifford & Co.	284,058	$1.85M	0.0%	-19.6%	0.214%
5/20/2024	Virtu Financial LLC	10,461	$87K	0.0%	N/A	0.008%
5/16/2024	Jacobs Levy Equity Management Inc.	1,675,403	$13.91M	0.1%	-0.5%	1.262%
5/16/2024	Bayesian Capital Management LP	38,600	$0.32M	0.0%	N/A	0.029%
5/16/2024	Caxton Associates LP	130,816	$1.09M	0.1%	-53.1%	0.099%
5/15/2024	Public Employees Retirement System of Ohio	94,341	$0.78M	0.0%	-4.1%	0.071%
5/15/2024	Bellevue Group AG	5,926,618	$49.19M	0.8%	-0.2%	4.465%
5/15/2024	Price T Rowe Associates Inc. MD	6,879,597	$57.10M	0.0%	-19.8%	5.183%
5/14/2024	American International Group Inc.	46,686	$0.39M	0.0%	+4.0%	0.035%
5/10/2024	Vanguard Group Inc.	11,815,669	$98.07M	0.0%	+10.9%	8.901%
5/8/2024	ProShare Advisors LLC	26,214	$0.22M	0.0%	+14.9%	0.020%
5/8/2024	Russell Investments Group Ltd.	179,972	$1.49M	0.0%	+57.2%	0.136%
5/7/2024	Susquehanna Fundamental Investments LLC	15,325	$0.13M	0.0%	N/A	0.012%
5/7/2024	Susquehanna Portfolio Strategies LLC	208,356	$1.73M	0.0%	-0.8%	0.157%
5/7/2024	Swiss National Bank	163,500	$1.36M	0.0%	+4.5%	0.123%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	54,917	$0.46M	0.0%	+7.2%	0.041%
5/1/2024	Baillie Gifford & Co.	353,226	$2.93M	0.0%	-5.5%	0.267%
4/30/2024	Allspring Global Investments Holdings LLC	9,569	$79K	0.0%	N/A	0.007%
4/29/2024	Principal Financial Group Inc.	25,775	$0.21M	0.0%	-6.8%	0.019%
4/29/2024	China Universal Asset Management Co. Ltd.	25,210	$0.21M	0.0%	+76.8%	0.019%
4/26/2024	Mesirow Financial Investment Management Inc.	17,627	$0.15M	0.0%	N/A	0.013%
4/19/2024	Mesirow Financial Investment Management Inc.	17,627	$0.15M	0.7%	N/A	0.013%
4/18/2024	Allspring Global Investments Holdings LLC	9,569	$79K	0.0%	N/A	0.007%
4/15/2024	TrueMark Investments LLC	54,445	$0.45M	0.4%	+13.5%	0.042%
4/11/2024	Congress Asset Management Co. MA	149,082	$1.24M	0.0%	+1.4%	0.114%
4/5/2024	Los Angeles Capital Management LLC	13,939	$0.12M	0.0%	+25.7%	0.011%
3/11/2024	Vanguard Group Inc.	10,650,387	$117.26M	0.0%	+0.9%	8.119%
2/15/2024	BVF Inc. IL	3,970,045	$43.71M	1.1%	+67.8%	3.115%
2/14/2024	Caxton Associates LP	279,101	$3.07M	0.2%	+637.3%	0.219%
2/14/2024	Pennant Investors LP	42,400	$0.47M	0.1%	N/A	0.033%
2/14/2024	Bellevue Group AG	5,936,082	$65.36M	1.0%	+21.5%	4.657%
2/13/2024	Affinity Asset Advisors LLC	300,000	$3.30M	0.6%	N/A	0.235%
2/13/2024	Rafferty Asset Management LLC	327,548	$3.61M	0.0%	-13.3%	0.257%
2/13/2024	Rhenman & Partners Asset Management AB	390,000	$4.29M	0.4%	+105.3%	0.306%
2/13/2024	NEOS Investment Management LLC	22,110	$0.24M	0.0%	N/A	0.017%
2/13/2024	Finepoint Capital LP	1,317,870	$14.51M	4.1%	+51.3%	1.034%
2/12/2024	TD Asset Management Inc	467,966	$5.15M	0.0%	-5.9%	0.367%
2/9/2024	Quest Partners LLC	13,380	$0.15M	0.0%	N/A	0.010%
2/9/2024	Trexquant Investment LP	128,890	$1.42M	0.0%	-35.1%	0.101%
2/9/2024	Dynamic Technology Lab Private Ltd	20,763	$0.23M	0.0%	+41.8%	0.016%
2/9/2024	Norges Bank	3,068,973	$33.79M	0.0%	N/A	2.408%
2/7/2024	Teacher Retirement System of Texas	18,357	$0.20M	0.0%	-18.2%	0.014%
2/7/2024	E Fund Management Co. Ltd.	17,486	$0.19M	0.0%	-9.9%	0.014%
2/6/2024	Charles Schwab Investment Management Inc.	877,813	$9.67M	0.0%	+22.8%	0.689%
2/6/2024	M&T Bank Corp	54,285	$0.60M	0.0%	+18.0%	0.043%
2/6/2024	Swiss National Bank	156,400	$1.72M	0.0%	-10.0%	0.123%
2/5/2024	Victory Capital Management Inc.	11,467	$0.13M	0.0%	N/A	0.009%
2/5/2024	Russell Investments Group Ltd.	114,488	$1.26M	0.0%	+1,766.8%	0.090%
2/1/2024	New York State Common Retirement Fund	36,678	$0.40M	0.0%	+3.2%	0.029%
2/1/2024	Handelsbanken Fonder AB	29,500	$0.33M	0.0%	+5.7%	0.023%
1/26/2024	Baillie Gifford & Co.	373,596	$4.11M	0.0%	-5.3%	0.293%
1/24/2024	DekaBank Deutsche Girozentrale	68,937	$0.76M	0.0%	+14.9%	0.054%
1/24/2024	China Universal Asset Management Co. Ltd.	14,257	$0.16M	0.0%	+354.8%	0.011%
1/16/2024	Raymond James Financial Services Advisors Inc.	58,353	$0.64M	0.0%	-2.8%	0.046%
1/16/2024	Raymond James & Associates	18,406	$0.20M	0.0%	-11.5%	0.014%
1/12/2024	SG Americas Securities LLC	91,973	$1.01M	0.0%	+139.4%	0.075%
1/11/2024	TrueMark Investments LLC	47,958	$0.53M	0.5%	N/A	0.039%
1/8/2024	Harbor Capital Advisors Inc.	38,064	$0.42M	0.1%	-7.6%	0.031%
1/5/2024	Exchange Traded Concepts LLC	14,962	$0.17M	0.0%	+34.0%	0.012%
12/18/2023	Vanguard Group Inc.	10,552,362	$88.75M	0.0%	+0.2%	8.560%
11/15/2023	GSA Capital Partners LLP	112,101	$0.94M	0.1%	+88.8%	0.091%
11/14/2023	MPM Bioimpact LLC	1,352,133	$11.37M	3.0%	-0.2%	1.097%
11/14/2023	Corton Capital Inc.	39,402	$0.33M	0.2%	+20.6%	0.032%
11/14/2023	Caxton Associates LP	37,854	$0.32M	0.0%	N/A	0.031%
11/14/2023	Trexquant Investment LP	198,671	$1.67M	0.0%	+926.5%	0.161%
11/14/2023	Profund Advisors LLC	63,931	$0.54M	0.0%	-43.5%	0.052%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	39,202	$0.33M	0.0%	N/A	0.032%
11/13/2023	Algert Global LLC	200,823	$1.69M	0.1%	+61.6%	0.163%

Data available starting January 2016

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.97

$7.69

$8.03

50 Day Range

MA: $7.60

$6.24

$9.51

52 Week Range

Now: $7.97

$5.70

$12.14

Volume

563,773 shs

Average Volume

1,428,409 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Who are the company insiders with the largest holdings of Relay Therapeutics?: Relay Therapeutics' top insider shareholders include:
Sanjiv Patel (CEO)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Thomas Catinazzo (CFO)
Brian Adams (Insider)
Andy Porter (Insider)
Learn More about top insider investors at Relay Therapeutics.
Who are the major institutional investors of Relay Therapeutics?: Relay Therapeutics' top institutional shareholders include:
Dimensional Fund Advisors LP — 1.15%
Logos Global Management LP — 0.98%
Millennium Management LLC — 0.86%
Renaissance Technologies LLC — 0.68%
Integral Health Asset Management LLC — 0.56%
Candriam S.C.A. — 0.53%
Learn More about top institutional investors of Relay Therapeutics stock.
Which institutional investors are selling Relay Therapeutics stock?: Within the last quarter, RLAY stock was sold by these institutional investors:
TD Asset Management Inc
Dimensional Fund Advisors LP
Baillie Gifford & Co.
Profund Advisors LLC
Federated Hermes Inc.
Caxton Associates LP
The Manufacturers Life Insurance Company
Principal Financial Group Inc.
During the previous year, company insiders that have sold Relay Therapeutics company stock include:
Sanjiv Patel (CEO)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Thomas Catinazzo (CFO)
Learn More investors selling Relay Therapeutics stock.
Which institutional investors are buying Relay Therapeutics stock?: Within the last quarter, RLAY stock was bought by institutional investors including:
Logos Global Management LP
Millennium Management LLC
Marshall Wace LLP
Driehaus Capital Management LLC
Candriam S.C.A.
Algert Global LLC
Renaissance Technologies LLC
Squarepoint Ops LLC